HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) announced on 19 November 2026 that China's National Medical Products Administration has granted simultaneous approval for two New Drug Applications for SYVIK® (sovleplenib) — one for chronic primary immune thrombocytopenia and one for warm antibody autoimmune haemolytic anaemia. The approvals make SYVIK® the first novel Syk inhibitor to receive regulatory clearance in China and represent HUTCHMED's first in-house discovered immunology drug approved for commercialisation. The milestone expands the company's commercial portfolio beyond oncology into immunology, addressing two chronic autoimmune blood disorders with significant unmet patient need.
Key Points
- HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13)
- China NMPA granted simultaneous approval of SYVIK® (sovleplenib) for both primary ITP and wAIHA on 19 November 2026
- SYVIK® demonstrated durable response rates of 48.4% versus zero for placebo in ITP (ESLIM-01) and 66% versus 15% for placebo in wAIHA (ESLIM-02); HUTCHMED retains full worldwide rights to sovleplenib
- Investors may be watching the pace of commercial launch in China and progress towards potential regulatory submissions in other markets
ESLIM-01 and ESLIM-02 Trial Data Underpin SYVIK® Approvals for ITP and wAIHA
The ITP approval is supported by data from ESLIM-01, a randomised, double-blinded, placebo-controlled Phase III trial enrolling 188 adult patients in China who had received at least one prior line of standard therapy. SYVIK® achieved a durable response rate of 48.4% compared with zero in the placebo arm, and overall response rates of 68.3% at zero to twelve weeks and 70.6% at zero to twenty-four weeks, versus 14.5% and 16.1% respectively for placebo, with all results reaching statistical significance (p<0.0001). The wAIHA approval draws on ESLIM-02, where SYVIK® produced a durable response rate of 66% versus 15% for placebo during weeks five to twenty-four, and an overall response rate of 70% versus 22%. Results from both studies were published in The Lancet Haematology.
SYVIK® Enters Large, Underserved Patient Populations Across China and Beyond
Approximately 110,000 patients are estimated to be living with primary ITP in China, according to figures cited in the announcement, with a further estimated 145,000 patients in major pharmaceutical markets excluding China. Warm antibody autoimmune haemolytic anaemia accounts for approximately 75–80% of all adult AIHA cases. Both conditions are characterised by chronic relapse and tolerability challenges associated with prolonged standard treatments, including corticosteroids. The simultaneous approvals in two indications therefore position HUTCHMED to address a broad, underserved population within China from the outset of commercialisation, extending the company's established oncology commercial infrastructure into immunology.
US FDA Orphan Drug Designation Supports Sovleplenib's Global Development Pathway
Beyond China, the US Food and Drug Administration granted sovleplenib Orphan Drug Designation for primary ITP and autoimmune haemolytic anaemia in October 2026, the announcement states. HUTCHMED retains full worldwide rights to sovleplenib and the company disclosed it continues to evaluate strategic pathways to support global development. The Orphan Drug Designation may provide certain regulatory and commercial incentives in the United States, though the company has not disclosed specific timelines or plans for a US regulatory submission at this stage.
Immunology Expansion Marks a Strategic Shift for HUTCHMED's Commercial Portfolio
HUTCHMED describes itself as an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialisation of targeted therapies and immunotherapies. The company already has five medicines marketed in China and one approved in the US, Europe, and Japan. The SYVIK® approvals mark the first time HUTCHMED has brought an in-house discovered immunology asset to full regulatory clearance, diversifying revenue potential beyond its oncology franchise. Key risks include the competitive landscape for autoimmune treatments in China, the ability to achieve reimbursement listing, and the inherent uncertainty of extending commercialisation to additional global markets.




Please wait processing your request...